Skip to main content
. 2012 Aug 24;2(4):e001450. doi: 10.1136/bmjopen-2012-001450

Table 1.

Clinical and pathological features of patients (data in parentheses are percentages)

Characteristics
No. of evaluable patients 279
Age (years)
 Median 65
 Range 29–97
Follow time (months)
 Median 46.32
 Range (0–137.16)
Stage
 I 181 (64.87)
 II 35 (12.54)
 III 43 (15.41)
 IV 20 (7.17)
Subtype
 Endometrioid 202 (72.4)
 CCC+serous 77 (27.6)
Grade (FIGO)
 1 119 (42.65)
 2 53 (19)
 3 107 (38.35)
Grade (nuclear)
 1 93 (33.33)
 2 75 (26.88)
 3 111 (39.78)
Tumour size (cm)
 ≤2 62 (22)
 >2 217 (78)
Depth of invasion
 Median 28
 Range 0–100
LVI
 No 202 (72.4)
 Yes 77 (27.6)
Lymph node status
 Positive 50 (17.92)
 Negative 135 (48.39)
 Unknown 94 (33.69)
Recurrence
 No 215 (77.06)
 Yes 47 (16.85)
 Persistent 12 (4.3)
 Progression 4 (1.43)
 Unknown 1 (0.36)
Status
 ANED 188 (67.38)
 AWED 22 (7.89)
 DOD 38 (13.62)
 DNED 22 (7.89)
 Dead unknown cause 1 (0.36)
 DWED 7 (2.51)
 Lost for FU 1 (0.36)

ANED, alive with no evidence of disease; AWED, alive with evidence of disease; CCC, clear cell carcinoma; DOD,  dead of disease; DNED, dead with no evidence of disease; DWED, dead with evidence of disease; FIGO, International Federation of Gynecology and Obstetrics; LVI, lymphovascular invasion.